Lombard Medical Technologies - A New Dawn

-->joeblogg1000
Over the course of the year I expect the stock to do well as it meets its milestones. The FDA reducing the number of implants required for the AAA stent graft trial plus allowing movement on to the second generation graft was double good news. The recent blip on production shows that making one type of graft in volume is hard enough without having to make two versions at the same time.

I still await news on the Investigational Device (IDE) filing with US FDA for the endostapler trial. This is the product Medtronic will sell. The $3M loan will come in handy to pay for this trial.

Another IDE filing due is for the long awaited Thoracic Graft.

If this company wants to be taken over rather than projects bought piecemeal it must show it has a pipeline of viable products. After the aortic and thoracic grafts there is the prospect for the low profile polymer inflated AAA graft so there is indeed a pipeline of lucrative products.